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Abstract
Background: Cardiovascular morbidity and mortality is very important in patients with chronic renal failure. This occurs
even in mild impairment of renal function and may be related to oxidative stress and chronic inflammation. The
nephrectomized apo E knockout mouse is an accepted model for evaluating atherosclerosis in renal dysfunction.
Erythropoietin derivates showed anti-oxidative and anti-inflammatory effects. Therefore, this study evaluates the effects of
Darbepoetin on markers of oxidative stress and chronic inflammation in atherosclerotic lesions in apo E knockout mice with
renal dysfunction.
Methods: Apo E knockout mice underwent unilateral (Unx, n = 20) or subtotal (Snx, n = 26) nephrectomy or sham operation
(Sham, n = 16). Mice of each group were either treated with Darbepoetin or saline solution, a part of Snx mice received a
tenfold higher dose of Darbepoetin. The aortic plaques were measured and morphologically characterized. Additional
immunhistochemical analyses were performed on tissue samples taken from the heart and the aorta.
Results: Both Unx and Snx mice showed increased expression of markers of oxidative stress and chronic inflammation.
While aortic plaque size was not different, Snx mice showed advanced plaque stages when compared to Unx mice.
Darbepoetin treatment elevated hematocrit and lowered Nitrotyrosin as one marker of oxidative stress, inflammation in
heart and aorta, plaque stage and in the high dose even plaque cholesterol content. In contrast, there was no influence of
Darbepoetin on aortic plaque size; high dose Darbepoetin treatment resulted in elevated renal serum parameters.
Conclusion: Darbepoetin showed some protective cardiovascular effects irrespective of renal function, i.e. it improved
plaque structure and reduced some signs of oxidative stress and chronic inflammation without affecting plaque size.
Nevertheless, the dose dependent adverse effects must be considered as high Darbepoetin treatment elevated serum urea.
Elevation of hematocrit might be a favorable effect in anemic Snx animals but a thrombogenic risk in Sham animals.
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Introduction
The prevalence and incidence of chronic kidney diseases (CKD)
have been continually increasing worldwide [1]. Nowadays,
cardiovascular events are the most important cause of morbidity
and mortality in patients with CKD [2]. The incidence of
myocardial infarction is threefold increased in CKD patients [3]
and sevenfold increased in patient on hemodialysis [4] when
compared to a matched healthy population. Several studies
showed that the elevation of risk starts even in mild impairment
of renal function [5,6].
CKD is regarded as a pro-inflammatory state and associated
with increased levels of oxidative stress [7,8]. Compared with a
renal healthy population CKD patients show elevated local
markers of oxidative stress like Nitrotyrosine (NT) [9] and systemic
inflammatory markers [10] like C-reactive protein (CRP) [11].
Pro-inflammatory cytokines and oxidative stress lead to endothe-
lial dysfunction [8] and to formation of fatty streaks, the early stage
of atherosclerosis [12]. Subsequent cell adhesion molecules like
intercellular adhesion molecule (ICAM) and vascular cell adhesion
molecule (VCAM) promote the formation of foam cells and
atherosclerotic plaques [13]. Inflammatory molecules influence
each other in a complex cascade while forming an atheroma [14].
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In the late phase interaction of CD40 and CD154 [15] may lead to
more advanced, more calcified plaques, activation of matrix
metalloproteases and destabilization of the plaques [10] may occur
with the risk of rupture and thrombembolia [16]. This risk is much
higher in CKD than in renal healthy patients [17]. Therefore
patients with CKD should be considered a high risk group for
cardiovascular diseases [18].
As rodents do not develop atherosclerosis spontaneously, even
when nephrectomized, Buzello et al. [19] introduced the models of
uni- and subtotally nephrectomized apo E knockout mice for
studying atherosclerosis in CKD showing a more aggressive
morphology of atherosclerotic plaques which increased in relation
to renal function impairment [19]. Bro et al. [20] and others [21]
confirmed these findings and proofed the involvement of
inflammation and oxidative stress via studying the change of cell
adhesion molecules [22], NT [23] or CRP [24]. Therefore, apo E
knockout mice are an accepted model for studying atherosclerosis
in CKD., Of note, atherosclerotic lesions in these mice are very
similar to those in human beings [25], although the presentation of
cardiovascular disease in patients with renal disease is often
atypical [26]. The apo E defect also leads to a dysregulation of the
anti-oxidative [27] and anti-inflammatory system [28] and
therefore to an advanced in-situ deposition of NT [29], a marker
of oxidative stress, and increased aortic expression of the adhesions
molecules ICAM and VCAM [20] in these mice.
Erythropoietin (Epo) derivates are widely known as therapeutic
agents in the treatment of anemia, especially of the renal form
[30]. It was recognized that cardiac function and capacity of
patients treated with Epo was increased [31]. Further studies were
undertaken to examine other possible protective effects of Epo
derivates, i.e. anti-apoptotic effects via inhibiting caspase 3 [31]
and stabilizing the BAX/Bcl-2-ratio in apo E deficient mice [32],
even in chronic renal failure [33]. Furthermore Epo diminishes the
production of inflammatory cytokines [34] and oxidative stress
[35]. Finally, Epo showed significant beneficial effects on the
morphology of atherosclerotic lesions of apo E knockout mice via
reducing the lipid content of macrophages and therefore foam cell
formation [36]. On the other hand it is important to consider
possible side effects of Epo like rapid elevation of hematocrit [37],
elevation of blood pressure [38] or an increased risk of thrombotic
emboli [38] via activation of thrombocytes [39]. Therefore, Epo
derivates were developed in order to profit from these protective
effects without being at risk of thromboembolia. Darbepoetin is a
long acting derivate of Epo which shows protective effects in doses
where it doesn’t elevate hematocrit [40]. Higher doses however do
elevate hemoglobin, which can lead to disturbed blood flow and
therefore increases risk of thrombembolic events, as shown in the
TREAT study [41]. Low dose Darbepoetin alpha also showed
protective effects on renal [42] and cardiac function [43]. Dursun
et al. investigated the effect of Darbepoetin alpha on atheroscle-
rosis in apo E knockout mice without CKD and showed changes in
proteomic profile of treated mice although plaque morphology was
not affected [44].
Therefore, it was the aim of the present study to evaluate possible
anti-oxidative and anti-inflammatory effects of two different doses of
Darbepoetin alpha on atherosclerotic lesions in Apo E knockout
mice with and without renal function impairment.
Materials and Methods
Animals and study design
Sixty-two apo E knockout mice were held at constant
temperature of 22uC and 50–60% humidity. The animals had
free admittance to standard diet (5% fat, 48% carbohydrates,
22.5% proteins) and water. At the age of three months mice were
randomly distributed to either unilateral (Unx), subtotal nephrec-
tomy (Snx) or sham operation (Sham) by a person not knowing any
laboratory findings of them.. Therefore, the left kidney was
removed, weighed and one week later a part of the right kidney
was also taken out corresponding to 2/3 of the weight of the left
kidney for Snx. For Sham operation the kidney capsule was
opened without withdrawal of any tissue. After another week each
group was divided in the following subgroups: One received saline
solution subcutaneous, one darbepoetin alpha at a dose of 11 mg/
kg body weight (‘‘normal dose’’) once a week for four months. In
the Snx-Group there was a third subgroup receiving 110 mg/kg
body weight Darbepoetin alpha (‘‘high dose’’) once a week for four
months. These doses were chosen according to the work of Egrie
Table 1. Plaque stages according to Rosenfeld et al. [46].
Score Criteria
1 Early plaque with foam cells
2 Plaque with cholesterol crystals
3 Advanced plaque with loss of lumen or fibrous cap, hemorrhage,
chondrocyte-like cells, layering or necrosis
doi:10.1371/journal.pone.0088601.t001
Table 3. Definition of plaque-score.
Score Expression
0 No expression
1 Weak expression (up to 25% dyeing)
2 Middle expression (up to 50% dyeing)
3 Strong expression (up to 75% dyeing)
4 Very strong expression (more than 75% dyeing)
doi:10.1371/journal.pone.0088601.t003
Table 2. Definition of the cholesterol-score.
Score Criteria
0 No cholesterol crystals
1 Few cholesterol crystals (approx. 25% of plaque area)
2 Several cholesterol crystals (approx. 50% of plaque area)
3 Many cholesterol crystals (approx. 75% of plaque area)
doi:10.1371/journal.pone.0088601.t002
Table 4. Definition of myocardial artery expression-score.
Score Expression
0 0 of 4 myocardial arteries were dyed
1 1 of 4 myocardial arteries were dyed
2 2 of 4 myocardial arteries were dyed
3 3 of 4 myocardial arteries were dyed
4 4 of 4 myocardial arteries were dyed
doi:10.1371/journal.pone.0088601.t004
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et al [45] where such doses caused at most a very modest elevation
of hematocrit in mice. The exact number of animals per group
and of animals that died during the study is shown in table S1. The
experiment was terminated after four months of treatment, i.e.
when animals were seven months of age, by perfusion fixation.
In contrast to Erythropoietin, which is traditionally measured in
activity units (U), the doses of Darbepoetin alpha are expressed in
mg. 1 mg of Darbepoetin alpha equals 200 U of Erythropoietin.
Ethics
All procedures performed on animals were done in accordance
with the NIH Guide for the Care and Use of Laboratory Animals
and were approved by the local government authorities (Regier-
ung von Mittelfranken, approval number AZ # 621-2531.31-13/
03) after evaluation by the local government’s review board for
animal research ethics. All surgery was performed under isoflurane
anesthesia, and all efforts were made to minimize suffering. If
judged necessary by a veterinarian, buprenorphine hydrochloride
was injected to prevent of relief suspected pain or discomfort.
Measurement of body weight, blood pressure,
hematocrit, serum and urinary parameters
Body weight was determined once per week, before blood
pressure measurements and before perfusion fixation using a high
precision scale. Blood pressure was measured via an intraarterial
catheter under isofluran anesthesia. Hematocrit was determined
every two weeks in whole blood from V. saphena magna, serum
parameters were analyzed right before perfusion fixation via
centrifugation of EDTA whole blood and urinary parameters were
determined from urine collected 24 h before perfusion fixation.
Creatinine clearance was calculated by measuring the concentra-
tion of creatinine in serum and urine over 24 hours.
Tissue preparation, morphologic and morphometric
investigations
The study was terminated by perfusion fixation. Briefly, the left
ventricle was punctured and flushed with 10% rheomacrodex to
dilate the vessels and prevent interstitial edema. Then the vascular
Table 5. Hematocrit.
Baseline (%) After Darbepoetin treatment (%)
After Saline treatment
(%)
Sham 51.763.08 60.868.13 52.963.50
Unx 51.163.64 59.869.07 53.966.88
Snx 44.862.08 59.667.88 49.168.89
Snx high 37.662.97 64.168.74 -
Kruskal-Wallis p,0.001 n.s. n.s.
Fisher Operation Sham/Unx/Snx p,0.001 n.s. p,0.05
Fisher before - after treatment p,0.05 (Sham/Unx)
p,0.001 (Snx)
n.s.
Mean 6 standard deviation.
n.s. = not significant;
doi:10.1371/journal.pone.0088601.t005
Table 6. Urea and creatinine.





Sham Control 51.4615.0 0.5860.70 29.6615.5 0.1360.17#
Darbepoetin 40.4615.9 0.0860.02 28.566.58u 0.4260.20
Unx Control 83.4642.7 0.2660.22 28.968.12# 0.2960.40
Darbepoetin 69.3622.1* 0.1160.02 20.566.25u 0.3060.07*
Control 87.3612.0 0.1760.04 24.868.33# 0.1660.09
Snx Darbepoetin 79.9610.4* 0.1660.03* 13.264.47 0.1760.08*,
Darbepoetin
high
108635.2 0.2460.11 17.263.26 0.1160.06
Kruskal-Wallis p,0.001 p,0.01 p,0.01 p,0.05
Fisher Operation Sham/Unx/Snx * p,0.001 vs. Sham
Darbepoetin
Control n.s.
* p,0.001 vs. Sham
Darbepoetin
Control n.s.
u p,0.001 vs. Snx
Darbepoetin
Control n.s.
* p,0.001 vs. Sham
Darbepoetin




n.s. n.s. Sham n.s. #p = 0.05 vs.
Darbepoetin respectively
# p,0.05 vs. Sham
Darbepoetin
Unx, Snx n.s.
Mean 6 standard deviation.
n.s. = not significant.
doi:10.1371/journal.pone.0088601.t006
Darbepoetin for Atherosclerosis in Renal Failure
PLOS ONE | www.plosone.org 3 February 2014 | Volume 9 | Issue 2 | e88601
system was rinsed with 0.9% NaCl for 10 minutes followed by
rinsing with glutaraldehyd-acid-buffer to harden tissue. After
5 min perfusion was stopped and the heart, the aorta and other
organs were taken out, fixed in 4% buffered formalin and
embedded in paraffine.
The aorta was sectioned into 3 mm thick paraffine sections,
every tenth section was stained with hematoxylin-eosin (HE) and
used for morphometric analyses. Thickness and area of aortic
media was measured using a semiautomatic image analyzing
system (analySISH) by building the arithmetic mean of 10
measurements. Total plaque volume was determined by multiply-
ing plaque area with the length of plaque containing aorta
ascendens. In the section next to the aortic valve plaque stage and
cholesterol crystals content were determined according to the
classifications in tables 1 [46] and 2.
Immunhistochemistry
Proteine expression of Nitrotyrosine (NT), ICAM, VCAM,
CRP, CD 40 and CD154 in aortic plaques and intramyocardial
arteries was determined by semiquantitative scoring (score 0–4) of
immunohistochemical staining (tables 3 and 4).
Aortic endothelium was evaluated as whether being stained (1)
or not (0) and the percentage of positively stained endothelia was
used for statistical comparisons.
Data regarding the used antibodies is provided in table S2.
Statistics
All statistical analyses were made with SPSS 21, SPSS Inc. Data
are given in mean 6 standard deviation apart from the
immunhistochemical analyses which are provided as scatterplots.
The non-parametric Kruskal-Wallis-Test followed by Fisher’s
exact test posthoc was used for comparison of means. Correlations
were calculated with Pearson’s correlation coefficient. Differences
were considered significant when p,0.05.
Results
Animal data
Baseline hematocrit of saline and Darbepoetin treated animals
was significantly lower in Snx than in Sham or Unx animals, the




Sham Control 91.8639.2 277691.9 181669.5
Darbepoetin 82.7636.7 298672.3 167632.5
Unx Control 83.8645.7 3216105 188660.6
Darbepoetin 70.0633.4 3896123 248673.3
Control 89.2624.0 393655.8 251670.7
Snx Darbepoetin 78.6625.2 299660.2 188657.4
Darbepoetin high 2886157 4366249 2656195
Kruskal-Wallis n.s. n.s. n.s.
Fisher Operation Sham/Unx/Snx n.s. n.s. n.s.
Fisher Medication Control/Darbepoetin n.s. n.s. n.s.
Mean 6 standard deviation.











Sham Control 104686.1 11.267.70 87.2616.4 295649.6
Darbepoetin 104667.7 15.0611.6 88.3613.5 301633.4
Unx Control 108663.8 15.569.60 87.5610.8 315634.5
Darbepoetin 112670.3 16.5610.7 93.669.62 336653.6
Control 79,167.73 16.368.60 90.767.90 302671.0
Snx Darbepoetin 170684.4 24.9613.2 84.167.62 268658.0
Darbepoetin high 101635.4 15.265.30 94.466.27 335654.8
One-way AOVA n.s. n.s. n.s. n.s.
Two-way ANOVA Operation Sham/Unx/Snx n.s. n.s. n.s. n.s.
Two-way ANOVA Medication Control/Darbepoetin n.s. n.s. n.s. n.s.
Mean 6 standard deviation.
n.s. = not significant;
doi:10.1371/journal.pone.0088601.t008
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Figure 1. Plaque stages and cholesterol content. Left row shows scatter plots of scores of plaque stage and plaque cholesterol content of the
seven treatment groups. Significant differences are marked with the certain significance level. Right row shows histological examples. Plaque stage of
Darbepoetin alpha treated Unx animal equals score 2 (arrows show cholesterol crystals) while plaque stages of Snx animal equals score 3 (arrows
show chondrocyte-like cells and necrosis). Cholesterol content of control Snx animal equals score 2 and that of Snx animal treated with high dose
Darbepoetin alpha equals score 1. Arrows show cholesterol crystals.
doi:10.1371/journal.pone.0088601.g001
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latter two groups did not differ. Mean hematocrit after
Darbepoetin alpha treatment was significantly higher than
baseline hematocrit in all groups. The changes in hematocrit after
saline treatment were not significant (table 5). Body weight did not
differ between the groups. In the treatment group, and partly by
trend in the control group, there was a significant increase in
serum-urea and serum-creatinine from Sham to Unx to Snx,
accompanied by a significant decrease in urine-creatinine
concentration, resulting in a significantly worse creatinine-
clearance, i.e. glomerular filtration rate (table 6). Darbepoetin
treatment led to further significant reduction of urine creatinine
concentration in Unx and Snx animals, especially some Snx
animal treated with the high dose of Darbepoetin alpha showed
very high levels of serum-urea, but to a significantly better
glomerular filtration rate in the Sham group. On blood pressure,
food or water consumption, albuminuria, albumin, phosphate,
serum cholesterol or lipids neither nephrectomy nor Darbepoetin
alpha treatment had any effect (table 7).
Plaque morphometry
Mean plaque area, plaque volume, media thickness and media
area showed no significant differences between the groups (table 8).
Figure 2. Nitrotyrosine plaque and myocardial artery score. Upper row shows nitrotyrosine staining score of plaque and intramyocardial
arteries. Significant differences are marked with the certain significance level. Lower row shows histological examples. Plaque staining increases
stepwise from Sham to Snx. Darbepoetin alpha treated examples show lower scores in each group.
doi:10.1371/journal.pone.0088601.g002
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Although plaque morphology was not significantly different Snx
animals showed significantly more advanced plaque stages than
Unx and also significantly more cholesterol crystals in the plaque
than Sham animals. Most importantly, Darbepoetin alpha
treatment significantly lowered plaque stage in the Unx group
and the amount of intraplaque cholesterol crystals in the Snx high
treatment group (fig. 1).
Nitrotyrosine (NT) as a marker of oxidative stress
The degree of NT staining in aortic plaques was significantly
influenced by impairment of renal function. It increased stepwise
from Sham to Unx to Snx with a significant difference between
Sham and Snx animals. Also the intramyocardial arteries showed
a significantly stronger expression of NT in parallel with lower
renal function (fig. 2). In the Darbepoetin alpha group Snx animals
showed a significantly higher percentage of NT positive aortic
endothelium than Unx animals (fig. 3). Of note, NT staining in
intramyocardial arteries correlated significantly positive with aortic
media thickness (p,0.05) and serum urea concentration (p,0.01).
Other markers of renal function showed correlations to NT
expression in plaque (with creatinine clearance: p = 0.06) or
intramyocardial arteries (with urine creatinine: p = 0.06; with
creatinine clearance: p = 0.07) by trend. Darbepoetin alpha
treatment also significantly influenced the protein expression of
NT in aortic plaques. In Snx animals a normal dose of
Darbepoetin alpha and additionally a high dose led to significantly
lower in-situ NT staining (fig. 2). No influence of Darbepoetin,
however, was seen on expression of NT in intramyocardial
arteries. Darbepoetin alpha treatment significantly lowered the
percentage of NT positive endothelium in Unx animals (fig. 3).
Markers of chronic inflammation
ICAM (Intercellular Adhesion Molecule). The protein
expression of ICAM in the aorta did not differ significantly
between the nephrectomy or treatment groups, neither in the
intramyocardial arteries or the aortic plaque (fig. 4) nor in the
aortic endothelium (data not shown).
VCAM (Vascular Cell Adhesion Molecule). VCAM in
intramyocardial arteries and aortic plaques was significantly
higher in Unx and Snx animals than in Sham (fig. 4). Of note,
expression in Snx was also significantly higher than in Unx.
Expression in the aortic plaques correlated negatively with the
urinary protein concentration. In the aortic endothelium there was
no significant difference (data not shown). Interestingly, Darbe-
poetin alpha treatment did not affect VCAM expression in the
heart or the aorta.
CRP (C-reactive protein). Nephrectomy showed a signifi-
cant influence on in-situ CRP protein expression in plaques and
intramyocardial arteries. There was a significantly higher CRP
expression in plaques in Unx and Snx mice than in Sham and a
stepwise increased expression from Sham over Unx to Snx in
intramyocardial arteries. CRP expression in intramyocardial
arteries correlated significantly with serum urea concentration
(p,0.01). Here, Darbepoetin alpha treatment significantly low-
ered CRP expression in Sham and Snx animals (fig. 5). In the
aortic plaques no such effect was seen.
In the aortic endothelium no significant effect of nephrectomies
or Darbepoetin alpha treatment was seen (table 9).
CD40. Protein expression of CD40 in aortic plaques and
intramyocardial arteries increased stepwise from Sham to Unx to
Snx. The difference between Sham and Snx was significant.
Darbepoetin alpha treatment led to lower CD40 expression with
the difference being significant in intramyocardial arteries whereas
in aortic plaques there was only a tendency for lower values (fig. 6).
In the aortic endothelium there was no significant difference
(table 9).
CD154. In aortic plaques protein expression of CD154 in
Unx and Snx animals was significantly higher than in Sham. This
effect was a little less pronounced in intramyocardial arteries and
Figure 3. Nitrotyrosine aortic endothelium score. Table shows nitrotyrosine staining score of aortic endothelia (0 or 1) and percentage of
positively stained endothelia per group. Significant differences are marked with the certain significance level. Right row shows histological examples.
The score of the Unx control animal equals 1 (arrows show stained areas of the endothelium) while the score of the Darbepoetin alpha treated Unx
animal equals 0.
doi:10.1371/journal.pone.0088601.g003
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therefore not significant. Darbepoetin alpha treatment had no
effect on the expression of CD154 in aortic plaques but
significantly lowered the protein expression of CD154 in
intramyocardial arteries of Unx mice (fig. 6). In the aortic
endothelium neither impairment of renal function nor Darbepoe-
tin alpha treatment led to significant changes of CD154 protein
expression (table 9).
Discussion
In the present study possible protective effects of the long acting
Epo analogue Darbepoetin alpha on the characteristics of
atherosclerosis in apo E knockout mice with chronic renal failure
were evaluated. As known by former studies, nephrectomy led to
increased expression of markers for oxidative stress and inflam-
mation in the cardiovascular system as well as to more advanced
atherosclerotic plaques. Treatment with Darbepoetin alpha
significantly lowered plaque stage and in-situ markers of inflam-
mation and oxidative stress. Furthermore hematocrit was elevated
dose dependently by the erythropoiesis stimulating agent Darbe-
poetin. In the high dose group hematocrit values exceeding the
upper physiological limit might have negative consequences as well
as elevated serum urea.
Figure 4. ICAM and VCAM plaque and myocardial artery score. Scatter plots of ICAM and VCAM staining score of plaque and intramyocardial
arteries of the seven treatment groups. Significant differences are marked with the certain significance level.
doi:10.1371/journal.pone.0088601.g004
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Most interestingly, intramyocardial arteries and aortic plaques
showed a stepwise increase of Nitrotyrosine (NT) protein
expression in Unx and Snx. In the aortic endothelium these
changes were not seen until Snx. The protein expression of NT
and also markers of inflammation correlated with renal function.
Other studies with apo E knockout mice also showed higher
expression of Nitrotyrosine in aortic plaques in severely reduced
renal function [19,20,29]. As these studies did not compare
different stages of renal function we are the first to show that NT, a
marker of oxidative stress, indeed increases proportionally to the
degree of renal impairment.
Also patients with CKD show elevated markers of oxidative
stress even at mild stages of renal dysfunction [47]. However, the
most pronounced effect was seen in patients with severely reduced
renal function [47] or patients undergoing dialysis [9].
Thus, our experimental data confirm findings of Cases et al.
[18] who showed that oxidative stress starts already in mild renal
dysfunction and increases stepwise with renal impairment.
In the present study Darbepoetin alpha treatment exerted its
anti-oxidative effect independently from renal function. It
significantly lowered in-situ NT expression in the aortic endothe-
lium in Unx and Snx and also in aortic plaques in Snx. This
finding in Snx apo E knockout mice, however, is in contrast to
findings of Bahlmann et al. in Snx rats where no significant
difference in the expression of the anti-oxidative enzyme
hemoxygenase under Darbepoetin alpha treatment was seen
[42]. This might be due to differences in the animal model or
much higher doses of Darbepoetin alpha in our study.
Impaired renal function is a well-known pro-inflammatory state
[13]. During an inflammatory reaction several markers are highly
expressed in the tissue. One of them is CRP which leads to
formation of foam cells [48] and up-regulation of cell adhesion
molecules [49]. They contribute to clotting of leucocytes on the
endothelium [50]. Also CD40 and CD154 regulate the secretion of
cell adhesion molecules [51] and also of MMPs [15], which
degrade extracellular matrix and destabilize plaques [52].
In the present study the protein expression of CD154 in aortic
plaques and the expression of CRP, ICAM and VCAM were
elevated already after Unx. After Snx the expression of CRP,
CD40 and VCAM in aortic plaques and of CD40 and CD154 in
intramyocardial arteries was elevated, too. Of note, the expression
of CRP in intramyocardial arteries correlated with serum urea
concentration. Therefore, the higher the degree of impairment of
renal function was, the more intense staining for inflammatory
markers in vessels and plaques was. When renal function is
severely impaired also other markers of inflammation are elevated:
Campean et al. showed that the number of CD154-positive cells in
coronary plaques of uremic patients was significantly higher than
in non-renal control patients. In this tissue the protein expression
of CD154 correlated with that of CRP and CD40 [53].
Treatment with Darbepoetin alpha significantly lowered the in-
situ expression of CRP in Sham animals, the local expression of
CD154 in Unx animals and that of CRP and CD40 in Snx
animals in intramyocardial arteries. This indicates an anti-
inflammatory effect of Darbepoetin alpha in every stage of renal
impairment. Beside this study there is no published work on the
anti-inflammatory effect of Darbepoetin alpha in impaired renal
function. But Darbepoetin alpha was already shown to lower pro-
inflammatory cytokines in patients with chronic cardiac insuffi-
ciency or anemia, respectively [54]. In contrast, the anti-
inflammatory effect of Epo was widely established in conditions
with [55,56] and without [57,58] impaired renal function.
In parallel to the decrease in renal function aortic plaque size
tended to increase continuously even though not significantly. Of
note, aortic plaques of Snx mice showed higher plaque stages with
a higher amount of cholesterol crystals. This was not yet seen in
Unx mice. Buzello et al. and Bro et al. also observed a steady
increase in plaque size from Sham to Unx and Snx and showed
that primary in Snx there was a change towards a more
inflammatory plaque phenotype with more macrophages and
cholesterol deposits [19,20]. Although we observed a slight
increase of plaque size according to renal dysfunction, the
differences were not significant. This is a limiting factor of the
Figure 5. CRP plaque and myocardial artery score. Upper row shows CRP staining score of plaque and intramyocardial arteries. Significant
differences are marked with the certain significance level. Lower row shows histological examples. Myocardial artery staining increases from Sham to
Snx. Darbepoetin alpha treated examples show lower scores in each group.
doi:10.1371/journal.pone.0088601.g005
Table 9. Expression of CRP, CD40 and CD154 in aortic endothelium.
CRP staining CD 40 staining CD154 staining
Median (%) pos. Median (%) pos. Median (%) pos.
Sham Control 0 20.0 0 20.0 0 20.0
Darbepoetin 0 14.3 0 28.6 0 42.9
Unx Control 0 42.9 0 42.9 0 42.9
Darbepoetin 0 28.6 1 85.7 0 28.6
Control 1 100 1 100 1 66.6
Snx Darbepoetin 1 66.6 1 66.6 1 55.5
Darbepoetin high 1 83.3 1 66.6 0 33.3
Kruskal-Wallis p,0.05 n.s. p,0.001
Fisher Operation Sham/Unx/Snx n.s. n.s. n.s.
Fisher Medication Control/Darbepoetin n.s. n.s. n.s.
Median and percentage of positive stained endothelia per group.
doi:10.1371/journal.pone.0088601.t009
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present study as it is in opposite to many other studies regarding
atherosclerosis in Apo E knockout mice [59–62]. One reason may
be that we used Apo E knockout mice which were reared in our
own animal laboratory. So there may be a slightly different gene
pool responsible for the missing significance. Other factors could
be found in a different timetable of animal surgery and treatment
between the studies as well as in a different way of measuring the
plaque size. We determined the total plaque volume via
microscopy in a distinct section of the ascending aorta as it has
been shown that this is the region where Apo E knockout mice
mainly develop plaques [63]. Other studies that found significant
differences partly evaluated the thoracoabdominal aorta, mea-
sured plaque area macroscopically in a lengthwise sectioned aorta
or determined plaque area in relation to aortic circumference.
This may explain the different results.
In humans it is also likely that even mildly reduced renal
function leads to larger plaques, because augmented plaque
formation [26] and an increased plaque score [64] were already
seen under such conditions. Like in animal models, progression to
higher plaque stages was only seen when renal function was
markedly impaired, as Schwarz et al. showed in uremic patients
[65]. Therefore it is a limitation of the present study that there was
no significant difference in plaque size according to renal function.
Treatment with Darbepoetin alpha did not influence plaque size
at all. But more dangerous than plaque size, is plaque instability
since this can, via rupture of their fibrous cap, lead to
thrombembolia and myocardial infarction [14,66]. The risk of
plaque rupture is linked to the total lipid content [66]. In the
present study treatment with Darbepoetin alpha significantly
lowered plaque stage and presumably the risk of plaque rupture.
In Snx animals especially the high dose treatment reduced the
content of cholesterol crystals. This effect might have been more
evident if the serum cholesterol concentration had also been
decreased and the serum lipid concentration had not increased.
Sham animals showed no difference. This presumed plaque
stabilizing effect of Darbepoetin alpha might also be of clinical
importance and seem to be present only when renal function is
markedly impaired.
In summary, although the number of animals in some groups
was limited, the present study confirmed the negative effects of
impaired renal function on the cardiovascular system particularly
atherosclerosis most likely via elevated oxidative stress and chronic
inflammation. Darbepoetin alpha treatment lowered in-situ
markers of oxidative stress and chronic inflammation irrespective
of renal function. It also led to lower heart weight and plaque stage
and therefore might exert a positive effect on cardiovascular risks
in a mouse model of chronic renal failure which may also have
implications in patients with CKD. However high dose treatment
not only lowered plaque content of cholesterol crystals but also
increased heart weight and serum urea, cholesterol and lipid
content. Hematocrit was elevated dose dependently, up to
unphysiological concentrations in high Darbepoetin alpha dose
group. The underlying pathomechanisms, however, which were
not addressed in greater detail in the present work, require further
studies.
Supporting Information
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